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Abstract
Tissue engineering is a rapidly expanding ﬁeld that aims to establish feasible techniques to fabricate biologically
equivalent replacements for diseased and damaged tissues/organs. Emerging from this prospect is the develop-
ment of in vitro representations of organs for drug toxicity assessment. Due to the ever-increasing interest in
ocular drug delivery as a route for administration as well as the rise of new ophthalmic therapeutics, there is
a demand for physiologically accurate in vitro models of the eye to assess drug delivery and safety of new ocular
medicines. This review summarizes current existing ocular models and highlights the important factors and lim-
itations that need to be considered during their use.
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Introduction
The human eye, a ﬂuid-ﬁlled sphere, is a unique and
highly protected organ with a complex anatomy and
physiology, containing several specialized structures
with distinct physiological functions. It is mainly di-
vided into two parts: the anterior and the posterior
segments. The anterior segment comprises the cornea,
conjunctiva, iris, ciliary body, aqueous humor, and
lens, and the posterior segment contains the sclera,
choroid, retina, and vitreous humor1 (Fig. 1).
In the anterior and posterior segments of the eye, oc-
ular barriers play an important part in controlling and
regulating the inward and outward transport of solutes,
ﬂuids, and also administered drugs. Upon topical ad-
ministration to the anterior part of the eye, drug mol-
ecules are prevented from reaching their ocular site of
action as a result of anterior static barriers (i.e., tight
junctions of corneal epithelium [CE] and blood–aque-
ous barriers) and also anterior dynamic barriers (i.e.,
lacrimal drainage and tear ﬂuid barrier, conjunctival
blood and lymphatic clearance). In addition, posterior
ocular tissue hinders drug permeation due to expres-
sion of efﬂux pumps on the cell membrane and also
by the presence of static (i.e., sclera, retinal pigment
epithelium [RPE], and blood capillary endothelial
cells) and dynamic barriers (i.e., choroidal blood and
lymph circulation).2 Therefore, the administered drug
is often required to overcome such ocular barriers
before reaching its site of action. For many years,
in vivo animal models have been used in ophthalmic
studies, mainly to evaluate the level of irritation and
toxicity of administered molecules to the ocular cells
and tissue. However, in recent years, due to cost, time,
and ethical issues associated with animal use,3,4 research-
ers have been encouraged to develop alternative tech-
niques for ocular investigations. These techniques
include ex vivo models of deceased animal tissue and
in vitro human and animal cell culture models. The
aim of this review is to provide an overview of the
established and recently constructed ocular models
and the advantages and limitations associated with
these models.
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Ocular Models
In vivo/ex vivo models
Animal experimentation plays an important role in the
research and development of ophthalmic drugs and oc-
ular delivery systems.3 For many years, live animals
have been utilized to assess the effect of various ocular
products to the eye.5,6 The rabbit is known as the most
commonly used animal model with larger animals such
as pigs, monkeys, dogs, and cats being less frequently
used. In addition, the value of mice and rats are limited
in ocular studies due to their small eye size.3
Following permanent eye injuries caused by a cos-
metic dye sold in the 1930s,7 the FDA developed the
rabbit in vivoDraize test for evaluating acute ocular tox-
icity.8 Draize test is an international standard assay in
which New Zealand white rabbits are mostly used as
they are readily obtainable, relatively inexpensive, and
have a well-described anatomy with large eyes.6 In this
protocol, 0.1mL of the test substance is applied onto
only one eye of the conscious rabbit, whereas the un-
treated eye serves as a control.8 After 72 h exposure of
the test substance on the cornea, conjunctiva, and iris,
chemicals can be classiﬁed on a subjective scoring,
which ranges from nonirritating to severely irritating.5
Despite its gold standard status and being the only
validated test for evaluating irritation severity in full
range, the Draize test has been criticized for numerous
limitations, including its time consuming and subjec-
tive nature of assessment, its lack of repeatability and
reproducibility,9 high dosage of test materials used,10
variable estimation of results, and overprediction of
human response,11 which is mainly related to interspe-
cies differences.
Consequently, the Draize test has been modiﬁed
both in protocol and data analysis from its original
form.12 In 1980, Grifﬁth and colleagues developed the
low volume eye irritation test (LVET), as an alternative
animal method and following a recommendation from
the National Research Council.13 In 1977, the National
Research Council committee suggested that the Draize
test drawbacks might be more of a volume–response
correlation rather than a species–response difference
between rabbits and humans. LVET is an alteration
to Draize testing in which test substances are only ap-
plied to the corneal surface of the rabbit’s eye and at a
lower volume (0.01mL vs. 0.1mL). The rationale in re-
ducing the instilled volume is that it is more represen-
tative of the lacrimal ﬂuid volume of both the human
and the rabbit eye. Therefore, the LVET was described
to cause less stress to tested rabbits and also results
could better predict human ocular irritation re-
sponse.11 However, results obtained following exposure
to severe irritants in LVET were considered to be an
underestimation of results in comparison with the
Draize data.14 Therefore, it is debatable whether to ac-
cept LVET as a more accurate test as it lacks the
FIG. 1. Schematic diagram of the human eye.
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element of exaggeration and overprediction of human
responses present in Draize testing.15–18 This, on the
other hand, raises concerns over assuring public safety
due to its moderate protocol.12,19 As a result, it is still
criticized for using animals and it has yet to be accepted
as an alternative test by regulatory agencies.
More recently, ocular organotypic models (Table 1)
have been used to minimize the use of live animals in
experimental studies. These isolated ocular systems re-
tain physiological and biochemical functions of the
mammalian enucleated eye or cornea.20,21 Opacity
and permeability of the isolated cornea under the effect
of a test substance is quantitatively measured using
opacitometry and spectrophotometry, respectively.
These measurements combined with histological anal-
ysis evaluate the extent of damage caused by the test
substance, and subsequently drive an eye irritation
classiﬁcation for prediction of potential in vivo ocular
irritation of a test substance.5,22
Burton et al. developed the ﬁrst ocular organotypic
model known as the isolated rabbit eye (IRE) test meth-
od.23 The IRE, also known as rabbit enucleated eye test,
was originally used to detect irreversible eye damage
caused by severe irritants.24 IRE protocols have devel-
oped over time and have been widely assessed by reg-
ulatory bodies (e.g., The European Commission/
British Home Ofﬁce).5 In 1997, an evaluation of the
test concluded that the assay lacks the ability to predict
irritation over the full range and can only be useful for
evaluating severe irritants.25 To date, IRE is mainly
used for nonregulatory optimization studies as it is
not characterized as a valid assay for ocular irritancy
classiﬁcation.26 In response to the deﬁciencies associ-
ated with IRE, Prinsen and Koe¨ter developed the iso-
lated chicken eye (ICE) test method.27 Chicken eyes
are readily available from slaughter houses with consis-
tent quality and dimensions that make them a practical
replacement for IRE. Toxic responses are measured by
changes in opacity, ﬂuorescein retention, thickness of
tissue upon swelling, and assessment of changes related
to the surface of the tissue.28
In addition, in 1992, Gautheron et al. developed the
bovine cornea opacity and permeability (BCOP) assay
based on methods originally developed by Muir29 and
Tchao.30,31 The BCOP assay was internationally ac-
cepted in 2009 and its scientiﬁc suitability is recognized
in identifying substances that can cause serious damage
as well as substances categorized as nonirritants.5
Using porcine cornea in BCOP is advantageous as it
more accurately resembles human cornea in terms of
thickness and structure and has also been frequently
used in ocular studies.32 These models have been able
to generate promising results with fewer ethical con-
cerns and at reduced costs. However, they all share
the mutual drawback that anatomical and physiological
differences among interspecies are still associated with
these tests. In addition, these models are only limited to
evaluating the corneal effects of the substances and not
the systemic effects. In 2007, the scientiﬁc advisory
committee of the European Center for the Validation
of Alternative Methods (ECVAM) issued a statement
on organotypic ex vivo assays as ocular screening
tests to detect possible corrosives and severe irritants.
Based on this statement, both BCOP and ICE test
methods are scientiﬁcally valid to identify severe ocular
irritants, whereas validation of the IRE method required
additional work to be performed and further review was
recommended.33
Tissue viability is prolonged when the culture medium
is periodically refreshed to retain sufﬁcient levels of sup-
plements and to eliminate metabolic waste products
from the cellular environment. Recently, bioreactors
Table 1. Ex Vivo Organotypic Models Used in Ocular Testing
Name Test method indicator Testing objective Validation status Limitations References
Bovine corneal
opacity and
permeability
(BCOP)
Increase in corneal
thickness, permeability,
and opacity
Ocular sensitivity
and corrosion
EVCAM statement of
scientific validity for
identification of severe
irritants and ocular
corrosives
Not as sensitive in
distinguishing
between mild irritants
with the standard
protocol
22,34
Isolated chicken eye
(ICE)
Increase in corneal
thickness, permeability,
and opacity
Ocular sensitivity
and corrosion
EVCAM statement of
scientific validity for
identification of severe
irritants and ocular
corrosives
Possible limitation for
solids
22,34
Isolated rabbit eye
(IRE)
Increase in corneal
thickness, and opacity
Ocular sensitivity
and corrosion
Further review is
recommended
Possible limitation for
solids
22,34
EVCAM, European Center for the Validation of Alternative Methods.
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that perfuse medium have enabled organotypic mod-
els to retain cell viability over an extended period of
time.35 Bioreactors are commonly described as devices
in which development of biological and/or biochemical
processes are under closely controlled environmental
and operating conditions (e.g., temperature, pH, oxygen,
pressure, medium ﬂow rate, pressure, nutrient supply,
and waste metabolite elimination).36,37 Perfusion culture
systems in bioreactors have shown to improve and pro-
long cell viability survival while maintaining cellular
functionality.38 Thuret et al. used an innovative bioreac-
tor for storage of ex vivo cornea, which maintained in-
traocular pressure and continuously renewed medium.
This allowed rapid reduction of stromal swelling and
improvement of endothelial cell viability in comparison
to the corneal immersion in a sealed ﬂask.39
In Vitro Cell-Based Models
Limitations associated with in vivo models have en-
couraged development and validation of various alter-
native in vitro models derived from animal and human
primary and immortalized cells. The exploitation of ap-
propriate in vitro models is crucial for the development
of new approaches to overcome ocular barriers. In
comparison with in vivo and ex vivo models, in vitro
cell-based models offer the advantage of being simple,
quick to construct, relatively inexpensive, and repro-
ducible, while providing mechanistic understanding
of the results.3,10 In addition, in vitro models can be
used to evaluate a number of combinations of experi-
mental parameters, which is often not achievable
with animal models.40,41 These models are commonly
used for basic science, pharmaceutical research and de-
velopment, toxicology, and permeability studies. The
use of both primary and immortalized cell culture
models of ocular barriers is described in the literature.
However, in vitro models based on primary cells have
limited cell division and growth in culture media, do
not retain cell characteristics beyond three or four
passages, and may also differ from isolate to isolate.
Therefore, the emphasis on various areas of ocular in-
vestigation has been on the development of in vitro
models based on animal and human immortalized
cell lines.12
Primary cells can be transformed using chemicals or
viruses to establish continuous/immortalized cells.
With immortalized cell lines, there is no longer a
need for the long process of tissue isolation, which is
followed by primary cell harvesting and cell puriﬁca-
tion. Furthermore, cells in culture are stable over a
greater passage number with the ability to rapidly
expand in growth medium if a large number of cells
are required for experiments. However, immortalized
cells may have altered growth characteristics, become
tumorigenic, and secrete abnormal levels of prote-
ases and cell surface markers. Moreover, expression
of many differentiated or tissue-speciﬁc enzymes can
be decreased and it is more likely for them to express
chromosomal abnormalities.42
Corneal morphology
The cornea is the outermost part of the anterior seg-
ment of the eye and is always in direct contact with
the external environment.43 The transparent and avas-
cular human cornea contains six layers (Fig. 2), and
has an average horizontal diameter of about 11.5mm,
a vertical diameter of 10.5mm, and an average radius
of curvature of 7.7mm curvature that remains constant
throughout life.44,45 About 90% of the corneal thick-
ness is made up of 200–250 uniformly spaced collage-
nous lamellae that intersect and run parallel to the
surface to cover the complete extent of the cornea.
This layer is called stroma, which offers corneal trans-
parency and physical strength.46 Five more layers make
up the remaining 10% of the cornea, which are the ep-
ithelium and Bowman’s layer at the front of the cornea
and Dua’s layer, Descemet’s membrane, and the endo-
thelium at the back of the cornea.47
The cornea is the major route of absorption for topi-
cally applied drugs, and CE tight junctions are the most
apical intercellular junctions that play an important
role in the establishment and maintenance of corneal
barrier function.48 The uppermost layers of CE cause
over 60% of corneal transepithelial electrical resistance
(TEER) and CE is known as the rate-limiting barrier
for transcorneal permeation. Therefore, models of the
cornea are very useful in studying drug permeation, ab-
sorption, and ocular toxicity. To date, cell cultured cor-
neal models range from simple monolayers to stratiﬁed
epithelium, to cocultures of epithelium and stroma,
and to more complex three-dimensional (3D) tissue-
engineered corneal equivalents.49
Corneal models
Corneal epithelial models. The CE is the outermost
layer of the eye, which acts as a major barrier of the
eye. Since the 1960s, many in vitro epithelial models
have been established as replacements to Draize test
based on primary and immortalized cell lines of
human and animal origin.50
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Primary models. Most of the primary cell culture
models (Table 2) that mimic corneal barrier are con-
structed from isolated corneal epithelial cells from rab-
bits.3 For instance, Kawazu et al. established a primary
rabbit corneal model which resembled the morphology
of an intact cornea and was used for studying perme-
ability of beta adrenergic antagonist and levoﬂoxacin51–53;
however, the model’s TEER and tight barrier were not
comparable to that of cornea in vivo.54,55 In another
study by Chang et al., a primary rabbit corneal epithelial
membrane was developed with more distinct barrier
properties due to air-interface culture conditions.56
Models of human primary epithelial cells have also
been investigated as toxicology models.5,57 Furthermore,
human primary corneal epithelial (HCE) cell has been
used for preparation of tissue sheets to reconstruct the
ocular surface in severe ocular surface disorders.58,59
Some authors, such as Ban et al., were successful in de-
veloping a stratiﬁed epithelium by culturing human cor-
neal limbal cells on human amniotic membrane, which
showed tight barrier junctions after 28 days in cul-
ture.60 However, the application of HCEs has been lim-
ited as alternative in vitro models of corneal barriers
due to the low availability of donor corneas.
Table 2. Summary of the Corneal Epithelial Models
Species Application(s) References
Primary
Rabbit Active transport studies
and permeability
51–53
Rabbit Permeability studies 56
Human Ocular irritation, toxicity,
and drug absorption
79–81
Immortalized
SIRC Corneal drug metabolism
and transport
65
EpiOcularTM Ocular sensitivity and corrosion 73
SkinEthicTM Ocular sensitivity and corrosion 74
Clonetics Ocular irritation and transepithelial
permeability studies
72
SIRC, Statens Seruminstitut rabbit corneal cells.
FIG. 2. Schematic presentation of different layers of the cornea.
Shafaie et al.; BioResearch Open Access 2016, 5.1
http://online.liebertpub.com/doi/10.1089/biores.2016.0008
98
Immortalized models
Animal. Various models of immortalized animal cor-
neal epithelial cells (Table 2) have been developed from
the rabbit,61,62 rat,63 and hamster.64 Models of immor-
talized rabbit CE cells are more commonly developed
and used compared with other animals. In addition, a
rabbit corneal cell line known as Statens Seruminstitut
rabbit corneal cells is widely used, despite showing a ﬁ-
broblast phenotype, which in turn decreases its value as
a valid model for CE.65 Although these models have
helped in reducing the use of animals, the issues related
with their nonhuman origin are still present.
Human. To overcome this limitation, since early 1990s,
considerable efforts have been focused on developing
in vitro models derived from human cells.66–69 Recently,
a large amount of research is being done in the ﬁeld of 3D
tissue engineering models.70,71 Examples of the in vitro
human-derived CE models that are commercially avail-
able as a 3D human cornea equivalents include: Epi-
OcularTM (MatTek), HCE (SkinEthic), and Clonetics
(Lonza). EpiOcular is a stratiﬁed, squamous epithelial
model in which a permeable polycarbonate membrane
is used to culture human epidermal keratinocytes from
neonatal human foreskin.72,73 Having an air–liquid inter-
face gives these models the advantage of exhibiting closer
morphological and growth characteristics to that of
in vivo conditions.22 Similar to the EpiOcular model,
HCE model of SkinEthicTM is developed from immortal-
ized human CEmucosa cells cultured at the air–liquid in-
terface using a polycarbonate substrate membrane. This
model is structurally very comparable to the corneal mu-
cosa of human eye due to the lack of stratum corneum in
the air–epithelial tissue.74 Both EpiOcular and SkinEthic
are currently used as an eye irritation test in place of the
Draize test for product development.69 Finally, Clonetics,
a model of human CE cells cultured on permeable mem-
brane supports and provides useful information on
assessing corneal penetration of ophthalmic drugs and
transepithelial permeability studies.75 In this model, the
lifespan of primary human corneal cells is extended by
infecting the cells with a recombinant retrovirus.76
In terms of model validation, both EpiOcular and Ski-
nEthic HCE models have undergone prospective valida-
tion by European Union Reference Laboratory for
alternatives to animal testing (EURL-ECVAM) and Cos-
metics Europe to distinguish potential irritants from
nonirritants.77,78 The EpiOcular model was found to be
acceptable only for the liquids and the protocol for test-
ing the solids required further optimization. It is now ac-
cepted for differentiating irritants from nonirritants,
however, EpiOcular model is not intended to distinguish
between categories of irritation. In addition, to date, the
SkinEthic HCE model is also validated for the testing of
liquids protocol, however solids protocol is still under-
taking additional optimization.78 Since these models
are developed based on noncorneal and immortalized
cell lines, there are some differences between them and
intact native human cornea, which should be taken
into account. For instance, primary mechanical or enzy-
matic detachment from corneal tissue would result in an
induced traumatic stimuli and a various range of re-
sponses from the cell.9 Consequently, this may affect
the integrity of cellular structure and cell differentiation.
In addition, the immortalization process followed by cul-
turing conditions may also alter gene expression; hence
the use of immortalized cell lines may not always truly
correlate with in vivo behavior of corneal cells.5 Addi-
tionally, due to the fragile nature of epithelial models,
they should be handled with great care to prevent cells
from drying or being damaged. In vitro cell-based assays
also lack the presence of hormonal, immune, and neural
inﬂuences, as well as cell–cell interactions. Although this
will result in a less complex model, it can also be a disad-
vantage for an organ as specialized and complex as the
eye since the interactions occurring throughout the
whole tissue are not taken into account.22
Corneal equivalents. Due to the limitations associated
with in vitro corneal epithelial models, several groups
have attempted to develop more complex multicellular
corneal equivalents. In comparison with models con-
sisting of only corneal epithelial cells, multicellular
models better replicate cellular interplay and character-
istics of native cornea.5 The ﬁrst model of a human cor-
neal equivalent from immortalized human corneal cells
was developed by Grifﬁth et al.82 This model is com-
posed of a thin layer of endothelial cells cultured on a
tissue culture dish with keratocytes and support pro-
teins in the middle covered with a layer of epithe-
lial cells. The stromal matrix was further improved
from the original study for understanding recovery
mechanisms83 and nerve–target cell interactions.84
Moreover, Reichl et al. (2004) developed a bioengi-
neered human cornea construct for permeation studies
containing immortalized endothelium and immortal-
ized stratiﬁed epithelium on top derived from HENC
and CEPI 17 Cl 4, respectively with native stromal cells
(ﬁbroblasts) in a collagen hydrogel matrix (Fig. 3).
Three different model drugs were used to test the
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barrier properties of this cornea equivalent model, such
as pilocarpine hydrochloride, befunolol hydrochloride,
and hydrocortisone.71 In addition to human corneal
equivalents, there are a few models of complete cornea
that have been derived from animal cells. The ﬁrst
in vitro model of the whole cornea was developed by
Minami et al. derived from isolated bovine endothelial,
stromal, and endothelial cells in a collagen gel matrix.85
Cornea-speciﬁc keratin was expressed by epithelial
cells and the epithelium was a 5–6 layer of superﬁcial
cells with microvilli, wing, and basal cells. In addition,
Zieske et al. have demonstrated feasibility of develop-
ing an in vitro model of all three corneal layers from
primary rabbit CE, keratocytes, and a mouse endothe-
lial cell line.86 Consequently, in vitro models of the ep-
ithelium, ﬁbroblasts, and endothelium from pig and
bovine were constructed for cytotoxicity testing of
chemicals and surfactants.87,88 Unfortunately, all mul-
ticellular in vitro models do not exhibit the complexity
of the native organ89 and factors such as the composi-
tion of the aqueous humor, tear ﬂuid, and tear ﬂow90
are not taken into account.
Conjunctival Morphology
The conjunctival epithelium is a transparent mucous
membrane containing only two to three cell layers
and lines the inner eyelid and anterior sclera to the
edge of the cornea. It serves as a protective barrier for
the ocular surface, generates mucus glycoproteins (mu-
cins) to facilitate eye lubrication and aids adherence of
tear ﬁlms. The conjunctiva is permeable to drugs of dif-
ferent size and polarity91,92 and plays an important part
in ocular and systemic absorption of topically adminis-
tered ophthalmic medications through the noncorneal
route.3,93 For a drug to cross the conjunctiva, a signif-
icant portion of it is lost to the systemic circulation
through the noncorneal route. This intraocular route
of drug entry is more applicable to large and hydro-
philic molecules that are poorly absorbed through the
cornea. The remaining part of the drug can diffuse
FIG. 3. Schematic presentation of a corneal equivalent in vitro culture model: (A) Corneal endothelial cells are
grown to conﬂuency on a culture insert. (B) A collagen layer containing stromal cells is grown on top of the
corneal endothelial cell layer. (C) Epithelial cells are seeded on top of the collagen layer. (D) Exposure to air–
liquid interface results in a stratiﬁed epithelium.71
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through sclera, which mainly contains collagen, and
unlike conjunctiva, is poorly vascularized. In vitro
models of conjunctival epithelium (Table 3) are useful
tools in understanding approaches to modulate ocular
noncorneal and systemic drug absorption.3
Conjunctival Models
To date, conjunctival epithelial cells have been mostly
derived from rabbit primary cells as submerged culture
models94–99 and the newer air–liquid interface cell cul-
ture systems.100–102 Recently, cell culture models of
conjunctiva were developed from primary bovine con-
junctival cells103 and immortalized rat cells.104 The
next step in establishing a functional in vitro conjunc-
tival model is to develop a system derived from human
conjunctival cells. Primary human conjunctival cul-
ture models are already used for conjunctival tissue
transplantation.105,106 In addition, two immortalized
human conjunctival cell lines have also become avail-
able and characterized,107,108 but have not yet been
used to develop an in vitro model of human conjuncti-
val epithelium.
Retinal Morphology
The retina lines the inner surface of the eye, surrounds
the vitreous cavity, and has an average thickness of
250 lm. It is designed to capture light and initiate pro-
cessing of the image by the brain. The retina is pro-
tected and held in position by the surrounding sclera
and cornea.45 The blood–retinal barrier (BRB) consists
of three layers: the outer BRB, known as the RPE, the
Bruch’s membrane, and the inner BRB, which is the
underlying choriocapillaris known as the retinal capil-
lary endothelium109 (Fig. 4). The RPE is a tight mono-
layer of epithelial cells, which regulates the transport of
nutrients and solutes, as well as the diffusion of sys-
temic drugs from the choroid into the retina and vitre-
ous humor.110 In contrast, the inner BRB is located in
the inner retinal microvasculature and contains the mi-
crovascular endothelium that lines these vessels. Diffu-
sion of many molecules from the blood to the retina is
hindered by the tight junctions located between these
cells, which are important in maintaining retinal ho-
meostasis.111 Several cell culture models of the inner
and outer BRB have been developed as useful tools
for investigating cell biology and transport functions
of RPE and retinal capillary endothelium (Table 4).
Retinal Models
Retinal pigment epithelium
Primary models. Primary cell culturemodels of RPEde-
rived from frog,112,113 rat,114,115 bovine,116 and chick117
have been widely described in the literature, however,
most researchers are interested in models based on
human RPE cells to avoid species-related applicability
problems. Primary culture models of human RPE118–120
have been used for drug uptake and transport,121–124 pro-
tein expression,125 and cytotoxicity studies.126–128 As
mentioned previously, there is limited availability of hu-
man donor eye cells in comparison with primary animal
cells.
Immortalized models. To date, utilizing immortalized
rat and human cell lines has led to different in vitro mod-
els of RPE being established.67,129–132 For instance, the
rat RPE-J cell line with highly differentiated phenotype
in vitro was developed by infection of rat primary RPE
cells with a SV40 virus.131 In addition, the ﬁrst sponta-
neously arising human RPE cell line was developed by
Davis et al. from a primary culture of human RPE.129
The cells showed the ability to mimic metabolic and
morphological properties of RPE cells in vivo, however,
due to the loss of enzymatic activities and cytoskeletal
polarization, the cell line is mainly used for cytotoxicity
studies133 rather than for the assessment of drug perme-
ation.3 Subsequently, Dunn et al.130 established and
characterized the second human immortalized RPE
cell line (ARPE-19) in terms of barrier properties and
expression of retina-speciﬁc markers. ARPE-19 cells
retained distinct cell borders and expressed retina-
speciﬁc markers, RPE65 and CRLABP. In addition,
due to the polarized distribution of cell surface markers,
the authors suggested this model to be suitable for polar-
ity studies in RPE cells.130 To more accurately reproduce
the in vivo RPE phenotype, culture conditions of RPE
cells have been altered, such as cocultivation with C6
Table 3. In Vitro Conjunctival Models Derived
from Primary Cells
Species
TEER
(O cm2) Application(s) References
Primary
Rabbit *1900 Active transport studies
and permeability
94–99
Rabbit *1100 Transport studies
and metabolism
100–102
Cow *5600 Toxicity studies 103
Immortalized
Conjunctival
(HCjE) cell line
Ocular surface
defence mechanism
107
TEER, transepithelial electrical resistance.
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glioma cells of immortalized astrocytes.134 However,
RPE-19 cell lines did not grow in coculture or under
conditioned medium mainly due to their heterogeneous
nature.4 A third immortalized human RPE cell line was
constructed by Bodnar et al., in which RPE cells were
transfected by vectors encoding for human telomerase
catalytic unit. As a result, the cellular life span was ex-
tended while cells retain normal growth characteristics
and gene expression patterns.132,135
RPE-19 cell lines have been used by researchers for var-
ious in vitro experiments, such as toxicity studies,136,137
gene delivery,138,139 polarity studies of proteins,140 and
as a model for retinal disease.137,141 However, the main
limitation associated with models of RPE-19 cells is the
long culture duration of up to 2 months for the cultured
RPE cells to become more growth quiescent.116,142 In ad-
dition, due to the limited availability of human donor
eyes, there are insufﬁcient primary RPE cell culture mod-
els for comparison in the characterization of RPE immor-
talized cell lines and validating the in vitro culture models
in terms of their in vivo/in vitro correlation. In addition,
morphological and functional appearance of the RPE
FIG. 4. Schematic presentation of the functions of the retinal pigment epithelium within the retina.
Table 4. Cell Culture Models of Blood–Brain Barriers
Species Application(s) References
Retinal pigment epithelium
Primary isolated bovine cells Assessment of barrier function 116
Primary isolated rat cells Assessment of tight junctions 114
Immortalized rat RPE-J cell line polarity and functions of the retinal pigment epithelium 131
Immortalized human cells (ARPE-19) Toxicity, gene delivery, and polarity studies 136,138,140
Retinal capillary endothelium
Primary isolated bovine retinal capillary (BRCEC) Permeability studies 147
Immortalized rat retinal capillary endothelium Barrier properties 146,149
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cultured cells is easily changed under cell culture condi-
tions, a phenomenon known as deadaptation, and it is
yet a challenge to develop a model of RPE that closely
mimics many specialized features of the RPE.143
Retinal capillary endothelium
Several pathogenic conditions of the eye such as dia-
betic retinopathy are related to the breakdown of the
inner BRB.144 Therefore, understanding the underly-
ing factors inﬂuencing the permeability of the reti-
nal capillary endothelium is essential for discovering
new treatment strategies for such diseases. To date,
in vitro models of retinal capillary endothelium have
been limited to primary isolated bovine retinal capillary
endothelial cells (BRCEC)145 and immortalized rat
retinal capillary endothelial cell line.146 Gillies et al.
studied the permeability of insulin, expression of blood–
brain barrier-related enzymes and effect of high glucose
levels on the permeability of a BRCEC monolayer us-
ing bovine retinal capillary endothelial model.147 This
model was further developed by Tretiach et al. as a co-
culture model of glial cells with primary BRCEC.148
However, this coculture model failed to grow as a
monolayer, and also the barrier properties of the Gillies
et al. model were not reproduced.145 In addition,
Hosoya et al. developed a conditionally immortalized
rat retinal capillary endothelial cell line,146 which was
further evaluated by Shen et al. in terms of barrier
properties.149 Such results concluded that so far, a ret-
inal capillary cell culture model with in vivo barrier
properties has not been developed. A better under-
standing of the in vivo barrier properties of the retinal
capillary endothelium, detailed characterization of cell
lines, and eventually coculture models will be necessary
to establish and scientiﬁcally validate a more accurate
in vitro model of the inner BRB.3
Ocular Disease Models
To date, a number of animal and cell culture models of
ocular diseases have been developed that help to inves-
tigate the molecular mechanism of ocular diseases and
to screen ophthalmic drug candidates. Age-related mac-
ular degeneration (AMD) is a leading cause of blindness
in people above the age of 60, which leads to visual im-
pairment and a high rate of depression.109 Due to the
unique features of the human eye and complexities asso-
ciated with the nature of the disease, animal models fail
to mimic all aspects of AMD.150 Therefore, cell culture
models of RPE cells are useful alternative tools to inves-
tigate the physiology and pathology of the disease. In ad-
dition, cell culture models are advantageous because
they are experimentally controlled systems and so the
results are more reproducible than those obtained
from animal models.3 A standard primary culture of
AMD is human fetal RPE, which closely models the
function and metabolic activity of native RPE.151
Other RPE cell models include RPE derived from stem
cells and the immortalized ARPE-19 cell line.130
In addition, diseases of the optic nerve are also
among the most devastating disorders in ophthalmol-
ogy, which can result in the degeneration of retinal
ganglion cell, visual ﬁeld loss and, potentially, blind-
ness. To date, the most useful glaucoma experimental
animal models are monkeys, rats, and mice in which
argon laser photocoagulation, diode laser photocoag-
ulation, or translimbal laser photocoagulation are
used to induce intraocular pressure. Although animal
models are essential to improve our knowledge and
to better understand the mechanism of each disease,
developing an animal model for a disease is com-
plex, challenging, and these animal models still differ
widely in their applicability to the human disease.152
Therefore, there are a range of cell culture models
of glaucoma, which include retinal ganglion cells,
mixed retinal cells, transformed retinal cells, and
neuronal-like cell lines. Once a culture model is estab-
lished, multiple mechanisms can be used to simulate
injury and study the effectiveness of neuroprotective
therapies.153
Vitreous Substitutes
The vitreous body is a gelatinous structure mainly
composed of hyaluronic acid and different types of col-
lagen (type II, IX, V/IX, and IV), which ﬁlls the space
between the lens and the retina. The stability of the vit-
reous structure is mostly dependant on the presence of
bound water to the glycosaminoglycans.154
Since 1960, clinical and bioengineering researchers
have attempted to ﬁnd an ideal vitreous humor substi-
tute that would replicate two aspects of the native
in vivo vitreous: on one hand, a substance with the
same molecular structure to ﬁll the ocular cavity and
to mimic the elasticity and pressure within the eye,
and on the other hand, presenting similar chemical
and physiological characteristics of this gelatinous sub-
stance to allow perfusion of drugs and diffusion of me-
tabolites.155,156 Some of the substances have been
known for more than 20 years, however, others have
been developed only recently to improve tolerability,
stability, and tamponade effect (Table 5).
Shafaie et al.; BioResearch Open Access 2016, 5.1
http://online.liebertpub.com/doi/10.1089/biores.2016.0008
103
3D In Vitro Models of the Eye
In vitro ocular cell culture models have been widely
used in various ﬁelds of research; toxicological screen-
ing, permeability, studies of drug uptake and transport,
cell physiology, and tissue engineering. They provide
useful data that compliment ﬁndings from in vivo stud-
ies and allow signiﬁcant reduction in the number of an-
imals used. However, there are intrinsic restrictions
associated with these models, mainly attributed to the
fact that such systems are cell monolayers grown on a
two-dimensional (2D) culture scaffold, which do not
take into account the response of cells in the 3D curved
environment present in the native ocular tissue.164 The
in vivo 3D microenvironment can send signals to a cell
through cell–cell or cell–extracellular matrix adhesion
and mechanical forces.40 Consequently, these signals
will activate a cascade of interactive events, which will
in turn inﬂuence cell proliferation, differentiation, cel-
lular structure morphology, and apoptosis.40 For in-
stance, in drug discovery research, a 2D in vitro cell
model that does not present accurate cellular properties
and barrier functions may lead to selection of a candi-
date that cannot reach its target side of action in vivo.
In addition, 3D cell culture provides more accurate de-
piction of cell polarization, since in 2D the cells can
only be partially polarized. Moreover, 3D cell cultures
have higher stability and longer lifespans than cell cul-
tures in 2D. Also, 3D aggregates can be cultured for a
longer period of time, at least up to 4 weeks, in compar-
ison with almost 1 week in a 2D monolayer culture due
to cell conﬂuency.40 Therefore, 3Dmodels are more ap-
propriate for demonstrating long-term effects of the
drug36 and to create robust and effective cell-based
platforms in pharmaceutical research so that cellular
responses will be more representative of those under
in vivo conditions.165
None of the commercially available in vitro ocular
models described in this review have been cultured
on curved scaffolds to mimic growth conditions of cor-
neal and retinal cells in vivo. In addition, ocular in vitro
models are limited to regional parts of the eye and no
model has yet been developed as an in vitro ocular
equivalent as an organ. Only recently, a study by Post-
nikoff et al.50 has taken into account curved cell growth
conditions, which focused on the creation of a 3D,
stratiﬁed, curved epithelium. In this study, human
papillomavirus-immortalized HCE cells were cultured
on a curved Millicell-HA membrane (mixed cellulose
esters; Millipore, Billerica, MA). This culture condition
led to a stratiﬁed, curved, epithelial model suitable for
assessment of cytotoxicity and biocompatibility testing
of contact lenses.50 Therefore, the availability of accu-
rate and informative 3D ocular in vitro models is an
important challenge for applications in ophthalmic re-
search, toxicity testing, and safety screening.
Conclusion
Every year, around 50–100 million animals, ranging
from zebra ﬁsh to nonhuman primates, are used
worldwide in animal experiments. In 2010, the total
number of animals used in the United States was al-
most 1.37 million, however, these statistics do not in-
clude rats and mice as these animals are not covered
by the Animal Welfare Act in the United States, but
still make up about 90% of research animals. In
2004, over 20,000 rabbits were used in the United
Kingdom for the Draize eye irritancy tests and by
2011, over three million animals were generally used
for experimentation, which mainly included mice
(71%), ﬁsh (15%), rats (7%), and birds (4%).166,167
In view of this and to minimize the use of animals, a
great amount of research has been dedicated to the
development of nonanimal alternatives wherever nec-
essary. Alternatives to animal studies are considered
as anything from complete to partial replacement of
live animals in biomedical research and experimental
studies.168 An apparent 40% decrease in animal use and
a simultaneous increase in the use of tissue culture and
biotechnology show that scientiﬁcally valid nonanimal
techniques are implementable.169
Table 5. Vitreous Experimental Substitutes
Types Examples Properties References
Natural polymers Hyaluronic acid and collagen Great biocompatibility; short degradation time;
low viscosity
157,158
Hydrogels Poly(vinyl alcohol) Poly(1-vinyl-2-pyrrolidone),
polyacrylamide
Great biocompatibility, stable transparency, and
viscoelastic properties
159–161
Transplants
and Implants
Artificial capsular bodies (foldable capsular
vitreous body)
Good mechanical, optical, and biocompatible
properties; may cause retinal disorders due to
long-term capsule-induced mechanical pressure
162,163
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The development of alternative ex vivo ocular models
has made important contributions to biological research.
The BCOP and the ICE test methods have been in devel-
opment since the early 1990s and are the ﬁrst ex vivo oc-
ular safety test methods that have been validated by the
regulators. In both cases, the animal eyes used in both
test methods are slaughterhouse waste, therefore ani-
mals were not speciﬁcally euthanized to obtain these
tissues. William Stokes, director of NICEATM and exec-
utive director of ICCVAM, estimated that using these
two assays alone could reduce the use of live animals
for eye safety testing by 10% or more.170
In addition, the use of in vitro platforms has been
greatly attributed to obvious cost and ethical advan-
tages over in vivo models. Finally, the development of
3D in vitro culture models that more closely replicates
in vivo and complements 2D cell culture and animal
model ﬁndings, will help researchers to feel conﬁdent
that ﬁnal decisions based on in vivo ocular models
are well supported.
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Abbreviations Used
2D ¼ two-dimensional
3D ¼ three-dimensional
AMD ¼ age-related macular degeneration
BCOP ¼ bovine cornea opacity and permeability
BRB ¼ blood–retinal barrier
BRCEC ¼ bovine retinal capillary endothelial cells
CE ¼ corneal epithelium
EURL ¼ European Union Reference Laboratory
EVCAM ¼ European Center for the Validation of Alternative
Methods
HCE ¼ human corneal epithelial
IRE ¼ isolated rabbit eye
LVET ¼ low-volume eye irritation test
RPE ¼ retinal pigment epithelium
SIRC ¼ Statens Seruminstitut rabbit corneal cells
TEER ¼ transepithelial electrical resistance
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